RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
Globe Newswire (Mon, 23-Mar 8:30 AM ET)
RenovoRx Raises $10 Million in Oversubscribed Private Placement
TipRanks (Mon, 23-Mar 7:30 AM ET)
Globe Newswire (Fri, 20-Mar 8:30 AM ET)
RenovoRx Announces $10 Million at Market Private Placement
Globe Newswire (Wed, 18-Mar 8:35 AM ET)
Globe Newswire (Fri, 27-Feb 8:30 AM ET)
Globe Newswire (Thu, 26-Feb 8:30 AM ET)
RenovoRx Establishes RenovoCath Medical Advisory Board
Globe Newswire (Tue, 10-Feb 8:30 AM ET)
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
Globe Newswire (Thu, 5-Feb 8:30 AM ET)
Globe Newswire (Wed, 4-Feb 8:30 AM ET)
Globe Newswire (Wed, 28-Jan 8:30 AM ET)
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Renovorx trades on the NASDAQ stock market under the symbol RNXT.
As of March 24, 2026, RNXT stock price declined to $1.08 with 617,016 million shares trading.
RNXT has a beta of 0.69, meaning it tends to be less sensitive to market movements. RNXT has a correlation of 0.02 to the broad based SPY ETF.
RNXT has a market cap of $51.07 million. This is considered a Micro Cap stock.
Last quarter Renovorx reported $266,000 in Revenue and -$.08 earnings per share. This fell short of revenue expectation by $-80,400 and met earnings estimates .
In the last 3 years, RNXT traded as high as $4.60 and as low as $.53.
The top ETF exchange traded funds that RNXT belongs to (by Net Assets): VTI, VXF.
RNXT has underperformed the market in the last year with a return of +12.5%, while SPY returned +17.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in RNXT shares. However, RNXT has outperformed the market in the last 3 month and 2 week periods, returning +18.7% and +35.0%, while SPY returned -4.8% and -3.4%, respectively. This indicates RNXT has been having a stronger performance recently.
RNXT support price is $1.04 and resistance is $1.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNXT shares will trade within this expected range on the day.
